RA Biologic's Serious Infection Risk Confounded by Order of Use RA Biologic's Serious Infection Risk Confounded by Order of Use
The risk for serious infection seen with tocilizumab is confounded by whether the drug is given as first-line or as subsequent treatment in the line of therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 28, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Govt makes interim allocation of COVID-19 treatment drug tocilizumab to states
In a letter, Pharma Joint Secretary Navdeep Rinwa and Health and Family Welfare Ministry Director Rajiv Wadhawan said the drug went out of stock in the country a few weeks ago due to a sudden surge in its demand because of a sharp rise in COVID-19 cases in the country. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 28, 2021 Category: Pharmaceuticals Source Type: news

Tocilizumab Preserves Lung Function in Early Systemic Sclerosis
Stabilization of lung function independent of the extent of quantitative radiographic interstitial lung disease or fibrosis at baseline (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 23, 2021 Category: Respiratory Medicine Tags: Dermatology, Pharmacy, Pulmonology, Radiology, Rheumatology, Journal, Source Type: news

Tocilizumab Preserves Lung Function in Early Systemic Sclerosis
FRIDAY, April 23, 2021 -- Tocilizumab prevents progression of interstitial lung disease in patients with early systemic sclerosis (SSc), according to a study recently published in Arthritis& Rheumatology. David Roofeh, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 23, 2021 Category: Pharmaceuticals Source Type: news

Govt issues updated clinical guidance for management of COVID-19 patients
The guidelines issued by AIIMS, ICMR-COVID-19 National Task Force and the Joint Monitoring Group (DGHS) under the ministry stated that tocilizumab (a drug that modifies the immune system or its functioning) may be considered in patients with significantly raised inflammatory markers and not improving despite use of steroids with there being no active bacterial/fungal/tubercular infection. (Source: The Economic Times)
Source: The Economic Times - April 23, 2021 Category: Consumer Health News Source Type: news

The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials, International Immunopharmacology
Analysis (8 RCTs, n=6314) found tocilizumab does not provide a survival benefit for patients with COVID-19 (mortality at day 28 = 24.4% and 29.9% in tocilizumab and control groups, respectively), but it may help reduce the risk of mechanical ventilation and ICU admission. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 21, 2021 Category: Consumer Health News Source Type: news

COVID-19 rapid guideline: managing COVID-19 [NG191], NICE (updated 8th April 2021)
This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together existing recommendations on managing COVID-19 so that healthcare staff and those planning and delivering services can find and use them more easily. The guideline includes new recommendations on therapeutics, and we will update the guideline further as new evidence emerges. 8 April 2021, Recommendations for using corticosteroids, tocilizumab and sarilumab to treat COVID-19 were added (including the evidence and rationale for making the recommendations). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 15, 2021 Category: Consumer Health News Source Type: news

Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report, Diagnostic microbiology and infectious disease
We present the case of a previously immunocompetent man with coronavirus disease-2019 who developed invasive pulmonary aspergillosis after treatment with tocilizumab, illustrating the importance of considering opportunistic infections when providing immune modulating therapy. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 15, 2021 Category: Consumer Health News Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic...
Source: Roche Investor Update - April 13, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic...
Source: Roche Media News - April 13, 2021 Category: Pharmaceuticals Source Type: news

Arthritis Drug May Curb Myocardial Damage in Acute STEMI Arthritis Drug May Curb Myocardial Damage in Acute STEMI
Tocilizumab appears to improve myocardial salvage by helping tamp down the inflammatory overshoot that occurs during infarction and reperfusion.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 13, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Providing patient information leaflets following COVID-19 treatment, SPS
Following treatment for COVID-19 with tocilizumab, sarilumab or steroids, clinicians should provide suitable patient information leaflets at discharge. Forms attached to this page can be used by clinicians with patients to support the discharge process. The materials have been developed in conjunction with Dhivya Subramaniam, NHS England and NHS Improvement. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 7, 2021 Category: Consumer Health News Source Type: news

Repurposing tocilizumab in scleroderma patients may prevent early lung disease
(Michigan Medicine - University of Michigan) A phase 3 clinical trial finds an anti-inflammatory drug used in rheumatoid arthritis can preserve lung function in patients with systemic sclerosis. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 31, 2021 Category: International Medicine & Public Health Source Type: news

Interleukin6 blocking agents for treating COVID19: a living systematic review, Cochrane Library
Authors ' conclusions On average, tocilizumab reduces all ‐cause mortality at D28 compared to standard care alone or placebo and probably results in slightly fewer serious adverse events than standard care alone or placebo. Nevertheless, tocilizumab probably results in little or no increase in the outcome clinical improvement (defined as hospital dischar ge or improvement measured by trialist‐defined scales) at D28. The impact of tocilizumab on other outcomes is uncertain or very uncertain. With the data available, we were not able to explore heterogeneity. Individual patient data meta‐analyses are needed to be able ...
Source: Current Awareness Service for Health (CASH) - March 25, 2021 Category: Consumer Health News Source Type: news

Can medicines that block interleukin-6 (a protein involved in immune responses) treat COVID-19?
This recently published Cochrane review examines the effects of a class of treatments on people with COVID-19.  Treating COVID-19 with tocilizumab (a medicine that blocks interleukin-6) reduces the numbers of people who die within 28 days of treatment, and probably results in fewer serious unwanted effects than placebo treatment.Studies of other medicines that block interleukin-6 to treat COVID-19 are under way. The authors of this review will update this review when results from them become available.COVID-19COVID-19 is an infectious respiratory disease caused by a type of virus called a coronavirus. If the infection bec...
Source: Cochrane News and Events - March 18, 2021 Category: Information Technology Authors: Katie Abbotts Source Type: news